JP2009533356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009533356A5 JP2009533356A5 JP2009504530A JP2009504530A JP2009533356A5 JP 2009533356 A5 JP2009533356 A5 JP 2009533356A5 JP 2009504530 A JP2009504530 A JP 2009504530A JP 2009504530 A JP2009504530 A JP 2009504530A JP 2009533356 A5 JP2009533356 A5 JP 2009533356A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- use according
- derivative
- acceptable salt
- list
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 19
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 11
- 208000002780 macular degeneration Diseases 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 239000002184 metal Substances 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 10
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- 201000007737 Retinal degeneration Diseases 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- 208000002492 retinal drusen Diseases 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 4
- 238000000034 method Methods 0.000 description 13
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79227806P | 2006-04-14 | 2006-04-14 | |
| US60/792,278 | 2006-04-14 | ||
| PCT/AU2007/000490 WO2007118276A1 (en) | 2006-04-14 | 2007-04-13 | Method of treatment of age-related macular degeneration(amd) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009533356A JP2009533356A (ja) | 2009-09-17 |
| JP2009533356A5 true JP2009533356A5 (enExample) | 2011-04-21 |
| JP5290147B2 JP5290147B2 (ja) | 2013-09-18 |
Family
ID=38608967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009504530A Expired - Fee Related JP5290147B2 (ja) | 2006-04-14 | 2007-04-13 | 加齢黄斑変性症（ａｍｄ）の処置方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20100144693A1 (enExample) |
| EP (2) | EP2012789B1 (enExample) |
| JP (1) | JP5290147B2 (enExample) |
| KR (2) | KR20100110396A (enExample) |
| CN (3) | CN102225930A (enExample) |
| AU (2) | AU2007240120A1 (enExample) |
| BR (2) | BRPI0722382A2 (enExample) |
| CA (1) | CA2683756A1 (enExample) |
| DK (1) | DK2012789T3 (enExample) |
| ES (1) | ES2437997T3 (enExample) |
| IL (1) | IL207495A (enExample) |
| NZ (2) | NZ572591A (enExample) |
| WO (1) | WO2007118276A1 (enExample) |
| ZA (2) | ZA200809493B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| US7973025B2 (en) | 2005-05-26 | 2011-07-05 | Neuron Systems, Inc. | Compositions and methods of treating retinal disease |
| CA2656825C (en) * | 2006-06-22 | 2013-12-10 | Prana Biotechnology Limited | Method of treatment and agents useful for same |
| JP2011530596A (ja) * | 2008-08-11 | 2011-12-22 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | ｔＲＮＡ合成酵素の阻害のためのハロフジノン類似体およびそれらの使用 |
| JP5719779B2 (ja) * | 2008-12-24 | 2015-05-20 | プラナ バイオテクノロジー リミティッド | キナゾリノン化合物 |
| KR20120078667A (ko) | 2009-01-26 | 2012-07-10 | 마이클 스피노 | 철 관련 안질환의 치료 및 예방을 위한 데페리프론의 용도 |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| WO2012122534A2 (en) | 2011-03-10 | 2012-09-13 | The Trustees Of Columbia University In The City Of New York | N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation |
| US10155742B2 (en) | 2012-01-13 | 2018-12-18 | President And Fellows Of Harvard College | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
| KR20150118106A (ko) * | 2012-12-20 | 2015-10-21 | 알데이라 테라퓨틱스, 아이엔씨. | 페리-카르비놀 |
| HK1217439A1 (zh) | 2013-01-23 | 2017-01-13 | Aldeyra Therapeutics, Inc. | 与毒性醛相关的疾病和治疗 |
| MX2015009444A (es) | 2013-01-25 | 2016-04-15 | Aldeyra Therapeutics Inc | Trampas novedosas en el tratamiento de la degeneracion macular. |
| EP3227292B1 (en) * | 2014-12-02 | 2022-03-09 | Alterity Therapeutics Limited | 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS |
| CN107533181B (zh) * | 2015-04-29 | 2020-06-30 | 特里亚佩克斯有限公司 | 偏光膜、制备它的方法及包含它的偏光镜片 |
| WO2017027064A1 (en) * | 2015-08-12 | 2017-02-16 | The General Hospital Corporation | 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents |
| MX2018002155A (es) | 2015-08-21 | 2018-06-08 | Aldeyra Therapeutics Inc | Compuestos deuterados y usos de los mismos. |
| WO2017053696A2 (en) * | 2015-09-24 | 2017-03-30 | University Of Florida Research Foundation, Incorporated | Halogenated quinoline derivatives as antimicrobial agents |
| CA3022665A1 (en) | 2016-05-09 | 2017-11-16 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| EP3478288A4 (en) * | 2016-07-01 | 2020-03-04 | Prana Biotechnology Ltd | METHOD OF TREATING IMMUNOGLOBULIN LIGHT-CHAIN AMYLOSIS |
| ES2968462T3 (es) | 2017-03-16 | 2024-05-09 | Aldeyra Therapeutics Inc | Sal polimórfica de 6-cloro-3-amino-2(2-hidroxiprolil) quinolina y usos de la misma |
| JP7311162B2 (ja) | 2017-10-10 | 2023-07-19 | アルデイラ セラピューティクス， インコーポレイテッド | 炎症性障害の処置 |
| EP3801525A4 (en) | 2018-06-08 | 2022-03-23 | The General Hospital Corporation | PROLYL TRNA SYNTHETASE INHIBITORS |
| WO2020033344A1 (en) | 2018-08-06 | 2020-02-13 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| CN109232396B (zh) * | 2018-11-27 | 2020-07-03 | 聊城大学 | 酰胺吡啶类衍生物及其用途 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| WO2020223685A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| WO2022006439A2 (en) * | 2020-07-02 | 2022-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compound embodiments for treating retinal degeneration and method embodiments of making and using the same |
| US12060334B2 (en) | 2021-03-12 | 2024-08-13 | University Of Florida Research Foundation, Incorporated | 3-substituted phenazine derivatives as antimicrobial agents |
| CN113214249B (zh) * | 2021-04-23 | 2023-09-19 | 成都大学 | 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE505711A (enExample) | 1950-09-09 | |||
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| HU178910B (en) * | 1977-08-19 | 1982-07-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing 2,3-disubstituted-4-oxo-4h-pyrido/1,2-a/-pyrimidines |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| IT1204612B (it) | 1987-05-14 | 1989-03-10 | Bioresearch Spa | Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica |
| US5314909A (en) * | 1993-03-17 | 1994-05-24 | Merck & Co., Inc. | Use of non-steroidal antiiflammatory agents in macular degeneration |
| JP3094373B2 (ja) | 1993-04-08 | 2000-10-03 | イデアール‐シユタンダルト ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 衛生水栓 |
| US5631373A (en) | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| DE4418096A1 (de) * | 1994-05-24 | 1995-11-30 | Cassella Ag | Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase |
| US6168776B1 (en) | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| US5801183A (en) | 1995-01-27 | 1998-09-01 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists |
| CN1114407C (zh) * | 1996-08-13 | 2003-07-16 | P·N·吉罗莱马托斯股份有限公司 | 螯合剂碘氯羟喹在制备用于治疗早老性痴呆的药物组合物中的用途 |
| GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| US5939421A (en) | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
| US20020025944A1 (en) * | 2000-04-28 | 2002-02-28 | Bush Ashley I. | Use of clioquinol for the therapy of Alzheimer's disease |
| US6337332B1 (en) * | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
| SK5222001A3 (en) | 1998-10-22 | 2002-05-09 | Neurosearch As | Substituted phenyl derivatives, their preparation and use |
| US6369058B1 (en) * | 1999-02-04 | 2002-04-09 | New Millennium Pharmaceutical Research Inc. | Brain delivery of folic acid for the prevention of alzheimer's disease and stroke |
| EP1216232B1 (en) | 1999-08-27 | 2006-10-11 | ChemoCentryx Inc | Heterocyclic compounds and methods for modulating cxcr3 function |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| WO2002068415A1 (en) | 2000-12-21 | 2002-09-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| FR2819187A1 (fr) * | 2001-01-10 | 2002-07-12 | Michel Xilinas | Utilisation des substances chelatrices pour le traitement et la prevention de la deferrescence oculaire |
| US7875612B2 (en) | 2001-04-24 | 2011-01-25 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| EP1427726A1 (en) | 2001-08-17 | 2004-06-16 | Merck & Co., Inc. | Process for preparing 5-sulfonamido-8-hydroxy-1, 6-naphthyridine-7-carboxamides |
| AU2003211560A1 (en) | 2002-02-20 | 2003-09-09 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
| ATE507210T1 (de) | 2002-03-07 | 2011-05-15 | X Ceptor Therapeutics Inc | Chinazolinon modulatoren von nukleinrezeptoren |
| AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| AU2002951868A0 (en) * | 2002-10-04 | 2002-10-24 | Prana Biotechnology Limited | Compound i |
| NZ539211A (en) * | 2002-10-04 | 2008-05-30 | Prana Biotechnology Ltd | Neurologically-active compounds |
| AU2004226876A1 (en) * | 2003-04-03 | 2004-10-14 | Prana Biotechnology Ltd | Treatment of neurological conditions |
| WO2004113277A2 (en) * | 2003-06-23 | 2004-12-29 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| DK1737831T3 (da) * | 2004-04-02 | 2013-08-19 | Prana Biotechnology Ltd | Neurologisk aktive forbindelser |
| US20110020237A1 (en) * | 2005-01-14 | 2011-01-27 | Glabe Charles G | Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders |
| US20080207673A1 (en) * | 2005-05-04 | 2008-08-28 | Michel Xilinas | Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins |
| CA2656825C (en) * | 2006-06-22 | 2013-12-10 | Prana Biotechnology Limited | Method of treatment and agents useful for same |
-
2007
- 2007-04-13 EP EP07718737.5A patent/EP2012789B1/en not_active Not-in-force
- 2007-04-13 CN CN2011101585377A patent/CN102225930A/zh active Pending
- 2007-04-13 KR KR1020107020805A patent/KR20100110396A/ko not_active Ceased
- 2007-04-13 ZA ZA200809493A patent/ZA200809493B/xx unknown
- 2007-04-13 US US12/297,165 patent/US20100144693A1/en not_active Abandoned
- 2007-04-13 AU AU2007240120A patent/AU2007240120A1/en not_active Abandoned
- 2007-04-13 NZ NZ572591A patent/NZ572591A/en not_active IP Right Cessation
- 2007-04-13 WO PCT/AU2007/000490 patent/WO2007118276A1/en not_active Ceased
- 2007-04-13 NZ NZ590271A patent/NZ590271A/en unknown
- 2007-04-13 EP EP12176495A patent/EP2514423A3/en not_active Withdrawn
- 2007-04-13 CN CN2010102559981A patent/CN101987849B/zh not_active Expired - Fee Related
- 2007-04-13 JP JP2009504530A patent/JP5290147B2/ja not_active Expired - Fee Related
- 2007-04-13 CN CNA2007800222734A patent/CN101534826A/zh active Pending
- 2007-04-13 ES ES07718737.5T patent/ES2437997T3/es active Active
- 2007-04-13 CA CA002683756A patent/CA2683756A1/en not_active Abandoned
- 2007-04-13 DK DK07718737.5T patent/DK2012789T3/da active
- 2007-04-13 BR BRPI0722382-0A patent/BRPI0722382A2/pt not_active Application Discontinuation
- 2007-04-13 KR KR1020087027935A patent/KR20080109096A/ko not_active Ceased
- 2007-04-13 BR BRPI0710737-4A patent/BRPI0710737A2/pt not_active IP Right Cessation
-
2010
- 2010-07-30 AU AU2010206074A patent/AU2010206074B2/en not_active Ceased
- 2010-08-09 IL IL207495A patent/IL207495A/en active IP Right Grant
- 2010-08-19 ZA ZA2010/05922A patent/ZA201005922B/en unknown
- 2010-11-23 US US12/952,425 patent/US20110071167A1/en not_active Abandoned
-
2013
- 2013-11-22 US US14/087,689 patent/US9163018B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009533356A5 (enExample) | ||
| JP2014506321A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| JP2012184234A5 (enExample) | ||
| EA200970933A1 (ru) | Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста | |
| RU2012145116A (ru) | Фармацевтическая композиция для предупреждения или лечения неалкогольного жирового гепатоза и способ предупреждения или лечения неалкогольного жирового гепатоза с ее использованием | |
| CN109311832A (zh) | 沃替西汀的帕莫酸盐及其晶型 | |
| JP2015523546A5 (enExample) | ||
| JP2023116697A5 (enExample) | ||
| JP2015522018A5 (enExample) | ||
| JP2014513065A5 (enExample) | ||
| JP2007504168A5 (enExample) | ||
| JP2011046708A5 (enExample) | ||
| WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
| JP2008534503A5 (enExample) | ||
| JP2008540528A5 (enExample) | ||
| JP2007530703A5 (enExample) | ||
| JP2006510659A5 (enExample) | ||
| EA201792565A1 (ru) | Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей | |
| WO2014047288A3 (en) | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2002522462A5 (enExample) | ||
| JP2013502449A5 (enExample) | ||
| JP2010526884A5 (enExample) | ||
| JP2003246730A5 (enExample) |